Tetracore competitors

Robert was appointed President and Chief Executive Officer of Cytokinetics in January 2007 and has been a member of our Board of Directors since then. Previously, he served as Cytokinetics’ President and held other senior-level positions at the Company overseeing research and development, finance, corporate development, legal, commercial operations, and business development at various times since participating in the launch of Company operations in 1998. Prior to Cytokinetics, Robert held senior positions in business development and marketing at COR Therapeutics from 1991 to 1998. He also performed roles of increasing responsibility in sales, marketing, and other pharmaceutical business functions at Marion Laboratories and Syntex Corporation beginning in 1981. Robert has served on the faculty at the Center for BioEntrepreneurship at University of California, San Francisco, where he taught a corporate finance course to graduate students. He co-chaired the BIO Business Development Committee and is a frequent lecturer on matters of business development and finance in the biopharmaceutical industry. He served on the National Board of the American Committee of the Weizmann Institute of Science and established the Blum Family Venture Philanthropy Fund to propel basic science discoveries at the Institute with potential to benefit the Israeli life sciences economy. In addition, he established the Tikkun Olam Youth Science Prizes for Bay Area middle and high schools, designed to further science education and exploration in the spirit of repairing the world. Robert served on the Board of the Jewish Community Federation of San Francisco and founded and chaired its Business Leadership Council. He also served on the Boards of San Francisco’s Contemporary Jewish Museum and the Anti-Defamation League. Robert was named a Henry Crown Fellow of the Aspen Institute in recognition of his leadership in corporate and civic responsibilities. He is a member of the Aspen Global Leadership Network and has moderated seminars related to science, health, and technology at Aspen Action Forums. Mr. Blum received B.A. degrees in Human Biology and Economics from Stanford University and an M.B.A. from Harvard Business School. Robert was a fan of mountain bluegrass music long before it was fashionable and has been known to carry a harmonica in his briefcase, much to the dismay of nearby hotel guests. He enjoys trying to keep up with his wife Dana and daughters, Brittany and Bridget, as well as his Bernese mountain dog, Baron, on long hikes in the Presidio.

Prior to joining Genocea,Chip co-founded and served as Chief Business Officer of Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA). Before that, Chip was a Principal at Care Capital, LLC, a venture capital firm investing in biopharmaceutical companies, after serving in a variety of commercial roles at SmithKline Beecham (now GlaxoSmithKline). Chip holds a B.A. from Harvard University and an M.B.A. from The Wharton School at the University of Pennsylvania.

Ken Siegel has over 25 years of experience as an executive and senior leader of major corporations. He currently serves as the Chief Executive Officer at SenesTech and as a member of the Board of Directors since 2019. Prior to joining SenesTech, Siegel served as President at Diamond Resorts International Inc. Previously, he was Chief Administrative Officer and General Counsel of Starwood Hotels & Resorts. Siegel’s experience includes all facets of corporate leadership including operations, strategy, finance, and administrative functions. An instrumental member of the Starwood leadership team, Siegel was intimately involved in Starwood’s emergence as an industry leader before its acquisition by Marriott International in 2016. Siegel played a pivotal role in Starwood’s transition to an asset-light business and was the architect of transactions that drove both top- and bottom-line benefits through industry-leading initiatives.

John Simard is a Chairman/President/CEO/Founder at XBiotech USA Inc, VP/Founder at MANNKIND CORP, and Board Member at MANNKIND CORP. He attended University of Toronto.

Chief Executive Officer and member of the board of XOMA (NASDAQ: XOMA). Joined XOMA in 2009 and was appointed to the CEO role in late 2016. In early 2017, Mr. Neal led XOMA through a dramatic strategic pivot taking the company from a traditional R&D heavy biotech company and transforming it to a successful royalty monetization and aggregation company. In the years prior to becoming CEO of XOMA, he was instrumental in leading the company’s licensing and business development activities focused on maximizing the value of XOMA’s foundational antibody IP and knowhow. In addition to his role at XOMA, Mr. Neal currently serves as a Director at Leading Biosciences, a clinical stage biotech company based in Carlsbad, CA. Mr. Neal has more than twenty years of experience in the biotechnology industry encompassing roles in R&D, business development, financing and general management. Prior to XOMA, Mr. Neal was Acting Chief Executive Officer of Entelos Inc., a leading bio-simulation company that acquired Iconix Biosciences, a privately held company where Mr. Neal was Chief Executive Officer. At Iconix, Mr. Neal established multi-year collaborations with Bristol-Myers Squibb, Abbott Labs (now AbbVie), Eli Lilly and the U.S. Food and Drug Administration. From 1999-2002, he was Executive Vice President of Incyte Genomics, leading global commercial activities with pharmaceutical company collaborators and partners including Pfizer, Aventis, GSK and others. Earlier in his career, he was an executive with Monsanto Company in positions of increasing responsibility. Mr. Neal earned his B.S. in Biology and his M.S. in Genetics and Plant Breeding from the University of Manitoba, Canada, and holds an MBA degree from Washington University in St. Louis, MO.

Skip Wagner is a President and Chief Executive Officer at BioReliance and is based in College Station, Texas.

Ron Squarer serves as Chairman and Executive Advisor at ADC Therapeutics SA (NYSE: ADCT) and directly supported the May 2020 company IPO. Mr. Squarer served as Chief Executive Officer and a member of the Array Biopharma Board of Directors from April 2012 through August 2019 when Pfizer Inc. acquired the company for $11.8 billion following the successful launch of the cancer treatments Braftovi® and Mektovi®. During his tenure, the company’s valuation grew ~40-fold through execution across research, development, and commercialization focused in the Oncology area. Array Biopharma’s research team is recognized for having invented Vitrakvi®/larotrectinib/TRK, Koselugo®/selumetinib/MEK, Tukysa®/tucatinib/HER2, ipatasertib/AKT, selpercatinib/RET, and MRTX849/KRAS-G12C among other molecules. Mr. Squarer has extensive commercial, development, research prioritization, and executive leadership expertise from a career spanning more than two decades in the biopharmaceutical industry. Before joining Array, Mr. Squarer held positions of increasing responsibility with Hospira, Inc., a global pharmaceutical and medical device company. In his last role there, as Senior Vice President and Chief Commercial Officer, he was responsible for delivering $4 billion in annual revenue. Mr. Squarer joined Hospira from Mayne Pharma, where he served as Senior Vice President, Global Corporate and Business Development when Mayne was sold to Hospira in 2007 for over $2 billion. Before Mayne Pharma, Mr. Squarer held leadership roles at both Pfizer, Inc. (including in Oncology), and SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) in the U.S. and Europe and currently serves as a member of the Board of Directors of Deciphera Inc. (NASDAQ: DCPH) and Travere Therapeutics Inc. (NASDAQ: TVTX) Mr. Squarer earned an MBA from the Kellogg School of Management, Northwestern University, and a bachelor’s degree in biochemistry from the University of California, Berkeley.

Highly motivated senior executive with general management experience in both large multi-national companies and small private equity environments in the diagnostic, medical device, pharmaceutical and life science industries. Demonstrated performance excellence in multi-disciplinary leadership roles including operations, marketing, sales, strategic planning, acquisitions and integrations on domestic and international level. Excel at turning around underperforming businesses with a combination of strong business acumen, outstanding leadership, customer relationships, and superior commercial execution. Dynamic leader with ability to build high performing teams and cross functional collaboration, align and inspire organizations towards a clear vision, and execute for sustainable results.